B7-H6 Antibody (1018457) [Alexa Fluor® 405]

• Reactivity: Hu
• Applications: B/N
• Clone: 1018457
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 405

B7-H6 Antibody (1018457) [Alexa Fluor® 405] Summary

• Immunogen: Human embryonic kidney cell HEK293-derived human B7-H6
  Asp25-Ser262
  Accession # Q68D85
• Specificity: Detects human B7-H6 in direct ELISAs.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Blockade of Receptor-ligand Interaction

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for B7-H6 Antibody (1018457) [Alexa Fluor® 405]

• B7 homolog 6
• B7H6
• B7-H6
• DKFZp686I21167
• DKFZp686O24166
• NCR3LG1

Background

B7-H6 is a glycosylated member of the B7 family of immune co-stimulatory proteins (1  2). Mature human B7-H6 consists of a 238 amino acid (aa) extracellular domain (ECD) that contains one Ig-like V domain and one Ig-like C1 domain, a 21 aa transmembrane segment, and a 171 aa cytoplasmic domain that contains one ITIM, one SH2, and one SH3 motif (3). Both of the Ig-like domains carry N-linked glycosylation (4). Within the ECD, human B7-H6 shares 99%, 94%, and 87% aa sequence identity with chimpanzee, orangutan, and gibbon B7-H6, respectively, and 53%-56% with bovine, canine, and equine B7-H6. Orthologs in mouse and rat have not been identified. The Ig-like V domain mediates 1:1 stoichiometric binding of B7-H6 to NKp30 expressed on NK cells (4, 5). It does not show binding to NKp44, NKp46, or NKG2D (3, 6). Ligation of NKp30 by B7-H6 induces NK cell activation and target cell cytolysis (3). B7-H6 is expressed on a wide range of hematopoietic, carcinoma, and melanoma tumor cells, which is consistent with the detection of NKp30 binding sites on many tumors (3, 7). The expression of NKp30 ligands on tumor cells correlates with tumor cell sensitivity to NKp30‑dependent cell lysis (7).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.